Children's persistence with methylphenidate therapy: a population-based study
Anton R Miller1, Christopher E Lalonde, Kimberlyn M McGrail
1Centre for Community Child Health Research, Children's and Women's Health Centre of British Columbia, Vancouver, British Columbia. amiller@cw.bc.ca
Insights
Methylphenidate (MPH) therapy shows significant variability in persistence among pediatric patients. Many children discontinue treatment early, highlighting the need for improved patient selection and monitoring strategies.
Area of Science:
- Pharmacology
- Pediatric Health
- Public Health
Background:
- Methylphenidate (MPH) is a commonly prescribed medication for children and youth.
- Understanding treatment persistence is crucial for optimizing therapeutic outcomes.
Purpose of the Study:
- To investigate the duration and patterns of methylphenidate (MPH) therapy persistence in a general pediatric population.
- To identify factors associated with MPH treatment adherence and discontinuation.
Main Methods:
- Retrospective analysis of linked prescription and health databases in British Columbia (1990-1996).
- Defined therapy cessation as a 4-month gap in prescription refills.
- Included 16,945 pediatric patients aged 19 years or under.
Main Results:
- Overall therapy duration averaged 584 days with 6.6 prescriptions.
- One-third of patients received 2 or fewer prescriptions, indicating low persistence.
- Younger children (0-8 years), males, and those initially prescribed by a psychiatrist showed greater persistence.
Conclusions:
- Significant variability in MPH persistence suggests potential issues in patient selection, preparation, and follow-up.
- Further attention is needed for older children and girls, and reasons for treatment discontinuities require investigation.
Objective:
To examine persistence with methylphenidate (MPH) therapy among children and youth in the general population.
Method:
We conducted a retrospective analysis of longitudinally organized, individual-specific anonymous data from linked prescription and health databases covering the population of British Columbia for 1990 through 1996. No prescriptions being filled for 4 months indicated cessation of one bout of therapy.
Results:
Among 16,945 identified MPH patients aged 19 years or under, overall duration of therapy was 584 days, and the average number of prescriptions received was 6.6. One-third of patients received 2 or fewer prescriptions, while 18% followed a chronic, continuous course. Among patients receiving more than 2 prescriptions, 50% of discrete therapy bouts lasted 4 months or less, and one-third of cases had multiple bouts of therapy (range 2 to 6 bouts). Younger age (that is, children aged 0 to 8 years, vs those aged 10 to 19 years), male sex, and receipt of initial prescription from a psychiatrist were associated with greater persistence.
Conclusions:
Enormous variability in persistence with MPH therapy and often-occurring low rates of persistence raises questions about the diligence with which MPH patients are selected, prepared, and followed in the general population. Special attention to the needs of older children and to the needs of girls is required, and discontinuities during children's therapy courses require explication.
Related Concept Videos
01:30Attention-Deficit/Hyperactivity Disorder
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
01:29Therapeutic Drug Monitoring: Affecting Factors
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption